Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3-4/2009

01-12-2009

Strategies for molecular expression profiling in bladder cancer

Authors: Anirban P. Mitra, Claudia C. Bartsch, Richard J. Cote

Published in: Cancer and Metastasis Reviews | Issue 3-4/2009

Login to get access

Abstract

Carcinoma of the urinary bladder involves alterations in multiple cellular pathways that dictate the pathology of the disease and clinical outcome of the patient. This includes alterations in regulation of the cell cycle, apoptotic mechanisms, signal transduction and tumor angiogenesis. Interrogation of alterations in multiple molecules associated with these pathways is leading to the development of biomarker panels that are capable of predicting an individual patient’s outcome or response to specific treatments. With respect to gene expression profiling, two broad approaches may be identified: a global approach and a pathway-specific approach. The global approach involves a high-throughput effort to profile the entire genome, while the pathway-specific approach quantifies select genes across several pathways. While the former has a high potential for discovery of novel signatures, the latter is important in generating reproducible and concise panels that have the potential for rapid clinical implementation. A combination of both these approaches is needed for the identification and validation of robust marker panels of potential clinical importance in bladder cancer.
Literature
1.
Heney, N. M. (1992). Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urologic Clinics of North America, 19(3), 429–433.PubMed
2.
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005). Global cancer statistics, 2002. CA A Cancer Journal for Clinicians, 55(2), 74–108.CrossRefPubMed
3.
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009). Cancer statistics. CA A Cancer Journal for Clinicians, 59(4), 225–249.CrossRefPubMed
4.
Pasin, E., Josephson, D. Y., Mitra, A. P., Cote, R. J., & Stein, J. P. (2008). Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Reviews in Urology, 10(1), 31–43.PubMed
5.
Mitra, A. P., Datar, R. H., & Cote, R. J. (2006). Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. Journal of Clinical Oncology, 24(35), 5552–5564.CrossRefPubMed
6.
Stein, J. P., Lieskovsky, G., Cote, R., Groshen, S., Feng, A. C., Boyd, S., et al. (2001). Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. Journal of Clinical Oncology, 19(3), 666–675.PubMed
7.
Mitra, A. P., Lin, H., Datar, R. H., & Cote, R. J. (2006). Molecular biology of bladder cancer: prognostic and clinical implications. Clinical Genitourinary Cancer, 5(1), 67–77.CrossRefPubMed
8.
Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S. C., et al. (1994). Accumulation of nuclear p53 and tumor progression in bladder cancer. New England Journal of Medicine, 331(19), 1259–1264.CrossRefPubMed
9.
Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z. F., Sheinfeld, J., Fair, W. R., et al. (1993). Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. Journal of the National Cancer Institute, 85(1), 53–59.CrossRefPubMed
10.
Serth, J., Kuczyk, M. A., Bokemeyer, C., Hervatin, C., Nafe, R., Tan, H. K., et al. (1995). p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. British Journal of Cancer, 71(1), 201–205.PubMed
11.
George, B., Datar, R. H., Wu, L., Cai, J., Patten, N., Beil, S. J., et al. (2007). p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. Journal of Clinical Oncology, 25(34), 5352–5358.CrossRefPubMed
12.
Cote, R. J., Esrig, D., Groshen, S., Jones, P. A., & Skinner, D. G. (1997). p53 and treatment of bladder cancer. Nature, 385(6612), 123–125.CrossRefPubMed
13.
Waldman, T., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1996). Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature, 381(6584), 713–716.CrossRefPubMed
14.
Mitra, A. P., Birkhahn, M., & Cote, R. J. (2007). p53 and retinoblastoma pathways in bladder cancer. World Journal of Urology, 25(6), 563–571.CrossRefPubMed
15.
Stein, J. P., Ginsberg, D. A., Grossfeld, G. D., Chatterjee, S. J., Esrig, D., Dickinson, M. G., et al. (1998). Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. Journal of the National Cancer Institute, 90(14), 1072–1079.CrossRefPubMed
16.
Mitra, A. P., Datar, R. H., & Cote, R. J. (2005). Molecular staging of bladder cancer. BJU International, 96(1), 7–12.CrossRefPubMed
17.
Simon, R., Struckmann, K., Schraml, P., Wagner, U., Forster, T., Moch, H., et al. (2002). Amplification pattern of 12q13–q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene, 21(16), 2476–2483.CrossRefPubMed
18.
Sanchez-Carbayo, M., Socci, N. D., Kirchoff, T., Erill, N., Offit, K., Bochner, B. H., et al. (2007). A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. Clinical Cancer Research, 13(11), 3215–3220.CrossRefPubMed
19.
Mitra, A. P., & Cote, R. J. (2009). Molecular pathogenesis and diagnostics of bladder cancer. Annual Review of Pathology, 4, 251–285.CrossRefPubMed
20.
Miyamoto, H., Shuin, T., Torigoe, S., Iwasaki, Y., & Kubota, Y. (1995). Retinoblastoma gene mutations in primary human bladder cancer. British Journal of Cancer, 71(4), 831–835.PubMed
21.
Cote, R. J., Dunn, M. D., Chatterjee, S. J., Stein, J. P., Shi, S. R., Tran, Q. C., et al. (1998). Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Research, 58(6), 1090–1094.PubMed
22.
Chatterjee, S. J., George, B., Goebell, P. J., Alavi-Tafreshi, M., Shi, S. R., Fung, Y. K., et al. (2004). Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. Journal of Pathology, 203(3), 762–770.CrossRefPubMed
23.
Lipponen, P. K., & Aaltomaa, S. (1994). Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. Journal of Pathology, 173(4), 333–339.CrossRefPubMed
24.
Perabo, F. G., Kamp, S., Schmidt, D., Lindner, H., Steiner, G., Mattes, R. H., et al. (2001). Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. British Journal of Cancer, 84(10), 1330–1338.CrossRefPubMed
25.
Yamana, K., Bilim, V., Hara, N., Kasahara, T., Itoi, T., Maruyama, R., et al. (2005). Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. British Journal of Cancer, 93(5), 544–551.CrossRefPubMed
26.
Wolf, H. K., Stober, C., Hohenfellner, R., & Leissner, J. (2001). Tumour Biology, 22(5), 328–336.CrossRefPubMed
27.
Gonzalez-Campora, R., Davalos-Casanova, G., Beato-Moreno, A., Garcia-Escudero, A., Pareja Megia, M. J., Montironi, R., et al. (2007). BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma. Cancer Letters, 250(2), 292–299.CrossRefPubMed
28.
Maluf, F. C., Cordon-Cardo, C., Verbel, D. A., Satagopan, J. M., Boyle, M. G., Herr, H., et al. (2006). Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment. Annals of Oncology, 17(11), 1677–1686.CrossRefPubMed
29.
Fitzgerald, J. M., Ramchurren, N., Rieger, K., Levesque, P., Silverman, M., Libertino, J. A., et al. (1995). Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. Journal of the National Cancer Institute, 87(2), 129–133.CrossRefPubMed
30.
Birkhahn, M., Mitra, A. P., Williams, A. J., Lam, G., Ye, W., Datar, R. H., et al. (2010). Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. European Urology, 57(1), 12–20.CrossRef
31.
Xia, G., Kumar, S. R., Hawes, D., Cai, J., Hassanieh, L., Groshen, S., et al. (2006). Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. Journal of Urology, 175(4), 1245–1252.CrossRefPubMed
32.
Mitra, A. P., Almal, A. A., George, B., Fry, D. W., Lenehan, P. F., Pagliarulo, V., et al. (2006). The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer, 6, 159.CrossRefPubMed
33.
Stephanou, A., Brar, B. K., Knight, R. A., & Latchman, D. S. (2000). Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death and Differentiation, 7(3), 329–330.CrossRefPubMed
34.
Mitra, A. P., Pagliarulo, V., Yang, D., Waldman, F. M., Datar, R. H., Skinner, D. G., et al. (2009). Generation of a concise gene panel for outcome prediction in urinary bladder cancer. Journal of Clinical Oncology, 27(24), 3929–3937.CrossRefPubMed
35.
Yao, H. Q., Peng, Y., Zhong, Z. Z., He, H. X., & Li, Z. H. (2004). Association of the expressions of platelet-derived growth factor receptor and c-Fos with the biological characteristics of bladder cancer. Di Yi Jun Yi Da Xue Xue Bao, 24(2), 177–179.PubMed
36.
Tiniakos, D. G., Mellon, K., Anderson, J. J., Robinson, M. C., Neal, D. E., & Horne, C. H. (1994). c-jun oncogene expression in transitional cell carcinoma of the urinary bladder. British Journal of Urology, 74(6), 757–761.CrossRefPubMed
37.
Bochner, B. H., Cote, R. J., Weidner, N., Groshen, S., Chen, S. C., Skinner, D. G., et al. (1995). Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. Journal of the National Cancer Institute, 87(21), 1603–1612.CrossRefPubMed
38.
Poon, E., Harris, A. L., & Ashcroft, M. (2009). Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Reviews in Molecular Medicine, 11, e26.CrossRefPubMed
39.
Theodoropoulos, V. E., Lazaris, A., Sofras, F., Gerzelis, I., Tsoukala, V., Ghikonti, I., et al. (2004). Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. European Urology, 46(2), 200–208.CrossRefPubMed
40.
Theodoropoulos, V. E., Lazaris, A. C., Kastriotis, I., Spiliadi, C., Theodoropoulos, G. E., Tsoukala, V., et al. (2005). Evaluation of hypoxia-inducible factor 1α overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU International, 95(3), 425–431.CrossRefPubMed
41.
Palit, V., Phillips, R. M., Puri, R., Shah, T., & Bibby, M. C. (2005). Expression of HIF-1alpha and Glut-1 in human bladder cancer. Oncology Reports, 14(4), 909–913.PubMed
42.
Crew, J. P., O'Brien, T., Bradburn, M., Fuggle, S., Bicknell, R., Cranston, D., et al. (1997). Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Research, 57(23), 5281–5285.PubMed
43.
Bernardini, S., Fauconnet, S., Chabannes, E., Henry, P. C., Adessi, G., & Bittard, H. (2001). Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. Journal of Urology, 166(4), 1275–1279.CrossRefPubMed
44.
Bochner, B. H., Esrig, D., Groshen, S., Dickinson, M., Weidner, N., Nichols, P. W., et al. (1997). Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer. Clinical Cancer Research, 3(9), 1615–1622.PubMed
45.
Grossfeld, G. D., Ginsberg, D. A., Stein, J. P., Bochner, B. H., Esrig, D., Groshen, S., et al. (1997). Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. Journal of the National Cancer Institute, 89(3), 219–227.CrossRefPubMed
46.
Chatterjee, S. J., Datar, R., Youssefzadeh, D., George, B., Goebell, P. J., Stein, J. P., et al. (2004). Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. Journal of Clinical Oncology, 22(6), 1007–1013.CrossRefPubMed
47.
Shariat, S. F., Tokunaga, H., Zhou, J., Kim, J., Ayala, G. E., Benedict, W. F., et al. (2004). p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. Journal of Clinical Oncology, 22(6), 1014–1024.CrossRefPubMed
48.
Shariat, S. F., Zlotta, A. R., Ashfaq, R., Sagalowsky, A. I., & Lotan, Y. (2007). Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Modern Pathology, 20(4), 445–459.CrossRefPubMed
49.
Shariat, S. F., Karakiewicz, P. I., Ashfaq, R., Lerner, S. P., Palapattu, G. S., Cote, R. J., et al. (2008). Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer, 112(2), 315–325.CrossRefPubMed
50.
Karam, J. A., Lotan, Y., Karakiewicz, P. I., Ashfaq, R., Sagalowsky, A. I., Roehrborn, C. G., et al. (2007). Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncology, 8(2), 128–136.CrossRefPubMed
51.
Birkhahn, M., Mitra, A. P., & Cote, R. J. (2007). Molecular markers for bladder cancer: the road to a multimarker approach. Expert Review of Anticancer Therapy, 7(12), 1717–1727.CrossRefPubMed
52.
Ørntoft, T. F., & Dyrskjøt, L. (2008). Gene signatures for risk-adapted treatment of bladder cancer. Scandinavian Journal of Urology and Nephrology Suppl, (218):166–174.
53.
Mitra, A. P., Lin, H., Cote, R. J., & Datar, R. H. (2005). Biomarker profiling for cancer diagnosis, prognosis and therapeutic management. National Medical Journal of India, 18(6), 304–312.PubMed
54.
Rosser, C. J., Liu, L., Sun, Y., Villicana, P., McCullers, M., Porvasnik, S., et al. (2009). Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiology, Biomarkers and Prevention, 18(2), 444–453.CrossRefPubMed
55.
Sanchez-Carbayo, M., Socci, N. D., Lozano, J. J., Li, W., Charytonowicz, E., Belbin, T. J., et al. (2003). Gene discovery in bladder cancer progression using cDNA microarrays. American Journal of Pathology, 163(2), 505–516.PubMed
56.
Modlich, O., Prisack, H. B., Pitschke, G., Ramp, U., Ackermann, R., Bojar, H., et al. (2004). Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clinical Cancer Research, 10(10), 3410–3421.CrossRefPubMed
57.
Blaveri, E., Simko, J. P., Korkola, J. E., Brewer, J. L., Baehner, F., Mehta, K., et al. (2005). Bladder cancer outcome and subtype classification by gene expression. Clinical Cancer Research, 11(11), 4044–4055.CrossRefPubMed
58.
Dyrskjøt, L., Thykjaer, T., Kruhoffer, M., Jensen, J. L., Marcussen, N., Hamilton-Dutoit, S., et al. (2003). Identifying distinct classes of bladder carcinoma using microarrays. Nature Genetics, 33(1), 90–96.CrossRefPubMed
59.
Aaboe, M., Marcussen, N., Jensen, K. M., Thykjaer, T., Dyrskjøt, L., & Ørntoft, T. F. (2005). Gene expression profiling of noninvasive primary urothelial tumours using microarrays. British Journal of Cancer, 93(10), 1182–1190.CrossRefPubMed
60.
Dyrskjøt, L., Kruhoffer, M., Thykjaer, T., Marcussen, N., Jensen, J. L., Moller, K., et al. (2004). Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Research, 64(11), 4040–4048.CrossRefPubMed
61.
Dyrskjøt, L., Zieger, K., Real, F. X., Malats, N., Carrato, A., Hurst, C., et al. (2007). Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clinical Cancer Research, 13(12), 3545–3551.CrossRefPubMed
62.
Dyrskjøt, L., Zieger, K., Kruhoffer, M., Thykjaer, T., Jensen, J. L., Primdahl, H., et al. (2005). A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clinical Cancer Research, 11(11), 4029–4036.CrossRefPubMed
63.
Wild, P. J., Herr, A., Wissmann, C., Stoehr, R., Rosenthal, A., Zaak, D., et al. (2005). Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clinical Cancer Research, 11(12), 4415–4429.CrossRefPubMed
64.
Sanchez-Carbayo, M., Socci, N. D., Lozano, J., Saint, F., & Cordon-Cardo, C. (2006). Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. Journal of Clinical Oncology, 24(5), 778–789.CrossRefPubMed
65.
Schultz, I. J., Wester, K., Straatman, H., Kiemeney, L. A., Babjuk, M., Mares, J., et al. (2006). Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: a microarray validation study. International Journal of Cancer, 119(8), 1915–1919.CrossRef
66.
Kuo, W. P., Jenssen, T. K., Butte, A. J., Ohno-Machado, L., & Kohane, I. S. (2002). Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics, 18(3), 405–412.CrossRefPubMed
67.
Zieger, K. (2008). High throughput molecular diagnostics in bladder cancer—on the brink of clinical utility. Molecular Oncology, 1(4), 384–394.CrossRefPubMed
68.
Ferre, F. (1992). Quantitative or semi-quantitative PCR: reality versus myth. PCR Methods and Applications, 2(1), 1–9.PubMed
69.
Schultz, I. J., Wester, K., Straatman, H., Kiemeney, L. A., Babjuk, M., Mares, J., et al. (2007). Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. European Urology, 51(2), 416–422.CrossRefPubMed
70.
Sanchez-Carbayo, M. (2003). Use of high-throughput DNA microarrays to identify biomarkers for bladder cancer. Clinical Chemistry, 49(1), 23–31.CrossRefPubMed
71.
Mitra, A. P., & Cote, R. J. (2007). Searching for novel therapeutics and targets: insights from clinical trials. Urological Oncology, 25(4), 341–343.
72.
Youssef, R. F., Mitra, A. P., Bartsch, G., Jr., Jones, P. A., Skinner, D. G., & Cote, R. J. (2009). Molecular targets and targeted therapies in bladder cancer management. World Journal of Urology, 27(1), 9–20.CrossRefPubMed
73.
Takata, R., Katagiri, T., Kanehira, M., Tsunoda, T., Shuin, T., Miki, T., et al. (2005). Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clinical Cancer Research, 11(7), 2625–2636.CrossRefPubMed
74.
Als, A. B., Dyrskjøt, L., von der Maase, H., Koed, K., Mansilla, F., Toldbod, H. E., et al. (2007). Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clinical Cancer Research, 13(15 Pt 1), 4407–4414.CrossRefPubMed
Metadata
Title
Strategies for molecular expression profiling in bladder cancer
Authors
Anirban P. Mitra
Claudia C. Bartsch
Richard J. Cote
Publication date
01-12-2009
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3-4/2009
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-009-9196-5

Other articles of this Issue 3-4/2009

Cancer and Metastasis Reviews 3-4/2009 Go to the issue

OriginalPaper

Emerging targeted therapies for bladder cancer: a disease waiting for a drug

OriginalPaper

Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer

EditorialNotes

Preface

OriginalPaper

Urothelial carcinoma: Stem cells on the edge

OriginalPaper

The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette–Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder

Acknowledgments

Biographies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits